Legacy Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Legacy Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-58	Closed	-$6K	–	204
2019 Q2	$6K	Hold	58	–	–	﹤0.01%	321
2019 Q1	$6K	Buy	+58	New	+$6.36K	﹤0.01%	357

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Legacy Advisors's IBB Position: Q3 2019 in Review

Legacy Advisors sold out of iShares Biotechnology ETF (IBB) in Q3 2019, closing a stake of 58 shares — an estimated $6K sold.

Legacy Advisors first reported a position in IBB in Q1 2019 and held it in 2 quarters. The position peaked at $6K in Q2 2019. 597 funds tracked by Wall St. Rank hold IBB as of Q3 2019.

Legacy Advisors reported no remaining iShares Biotechnology ETF position as of Q3 2019 after selling out during the quarter.
Legacy Advisors sold 58 iShares Biotechnology ETF shares in Q3 2019, an estimated $6K.
Legacy Advisors first reported a position in iShares Biotechnology ETF in Q1 2019 and held it in 2 quarters.
Legacy Advisors's iShares Biotechnology ETF position peaked at $6K in Q2 2019.
597 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2019.

Based on Legacy Advisors's 13F filing for Q3 2019, filed 10 Oct 2019.